June 13, 2024



FDA will decide on whether to fully approve Pfizer’s COVID-19 vaccine by January 2022

Daily Mail.com

The U.S. Food and Drug Administration (FDA) will decide on full approval of Pfizer-BioNTech’s COVID-19 vaccine for those aged 16 and older no later than early next year.  

Currently, the two-dose shot is only authorized for emergency use in Americans aged 12 and up.

However, the FDA granted Priority Review to Pfizer-BioNTech’s application, meaning all overall attention and resources are directed at reviewing data on the vaccine.

Read more…